Table 2 Patient’s characteristics according to TROP2 expression.

From: Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapy

Different variables

All pats

n = 110 (%)

TROP2 (Int. × Prop.)

TROP2 (Prop.)

TROP2 (Int.)

 < 12

n = 64 (58.2%)

12

n = 46 (41.8%)

p-value

 < 4

n = 42 (38.2%)

4

n = 68 (61.8%)

p-value

 < 3

n = 46 (41.8%)

3

n = 64 (58.2%)

p-value

Age

 < 75

72 (65.5)

46 (71.9)

26 (56.5)

0.095

29 (69.1)

43 (63.2)

0.533

33 (71.7)

39 (60.9)

0.240

 ≥ 75 yrs

38 (34.6)

18 (28.1)

20 (43.4)

 

13 (31.0)

25 (36.8)

 

13 (28.3)

25 (39.1)

 

Sex

Male

89 (80.9)

54 (84.4)

35 (76.1)

0.275

35 (83.3)

54 (79.4)

0.611

39 (84.8)

50 (78.1)

0.381

Female

21 (19.1)

10 (15.6)

11 (23.9)

 

7 (16.7)

14 (20.6)

 

7 (15.2)

14 (21.9)

 

ECOG PS

0–1

87 (79.1)

53 (82.8)

34 (73.9)

0.260

34 (81.0)

53 (77.9)

0.706

39 (64.8)

48 (75.0)

0.213

2–3

23 (20.9)

11 (17.2)

12 (26.1)

 

8 (19.1)

15 (22.1)

 

7 (15.2)

16 (25.0)

 

Smoking Index

Yes

92 (83.6)

54 (84.4)

38 (82.6)

0.805

5 (11.9)

13 (19.1)

0.321

7 (15.2)

11 (17.2)

0.783

No

18 (16.4)

10 (15.6)

8 (17.4)

 

37 (88.1)

55 (80.9)

 

39 (84.8)

53 (82.8)

 

Histology

AD

56 (50.9)

36 (56.3)

20 (43.5)

0.186

20 (47.6)

36 (52.9)

0.588

27 (58.7)

29 (45.3)

0.166

Non-AD

54 (49.1)

28 (43.8)

26 (56.5)

 

22 (52.4)

32 (47.1)

 

19 (41.3)

35 (54.7)

 

Liver meta

Yes

15 (13.6)

9 (14.1)

6 (13.0)

0.877

6 (14.3)

9 (13.2)

0.876

6 (13.0)

9 (14.1)

0.878

No

95 (83.4)

55 (85.9)

40 (87.0)

 

36 (85.7)

59 (86.8)

 

40 (87.0)

55 (85.9)

 

Brain meta

Yes

19 (17.3)

15 (23.4)

4 (8.7)

0.044

5 (11.9)

14 (20.6)

0.242

12 (26.1)

7 (10.9)

0.038

No

91 (82.7)

49 (76.6)

42 (91.3)

 

37 (88.1)

54 (79.4)

 

34 (73.9)

57 (89.1)

 

Bone meta

Yes

31 (28.2)

18 (28.1)

13 (28.7)

0.988

9 (21.4)

22 (33.4)

0.216

14 (30.4)

17 (26.6)

0.656

No

79 (71.8)

46 (71.9)

33 (71.7)

 

33 (78.6)

46 (67.7)

 

32 (69.6)

47 (73.4)

 

Response

PR

41 (37.3)

29 (45.3)

12 (26.1)

0.040

19 (45.2)

22 (32.4)

0.175

21 (45.7)

20 (31.3)

0.123

Non-PR

69 (62.7)

35 (54.7)

34 (73.9)

 

23 (54.8)

46 (67.7)

 

25 (54.4)

44 (68.8)

 

PD-L1(%)

 ≥ 1

61 (55.5)

36 (57.1)

25 (55.6)

0.870

21 (51.2)

40 (59.7)

0.388

27 (60.0)

34 (54.0)

0.533

 < 1

47 (44.5)

27 (42.9)

20 (44.4)

 

20 (48.8)

27 (40.3)

 

18 (40.0)

29 (46.0)

 

Any irAEs

Yes

77 (70.0)

47 (73.4)

30 (65.2)

0.353

34 (81.0)

43 (63.2)

0.049

33 (71.7)

44 (68.8)

0.736

No

33 (30.0)

17 (26.6)

16 (34.8)

 

8 (19.1)

25 (37.7)

 

13 (28.3)

20 (31.3)

 

G3/4 irAEs

Yes

37 (33.6)

21 (32.8)

16 (34.8)

0.829

14 (33.3)

23 (33.8)

0.958

16 (34.8)

21 (32.8)

0.829

No

73 (66.4)

43 (67.2)

30 (65.2)

 

28 (66.7)

45 (66.2)

 

30 (65.2)

43 (67.2)

 

NLR

High

52 (47.3)

30 (46.9)

22 (47.8)

0.922

21 (50.0)

31 (45.6)

0.653

24 (52.2)

28 (47.8)

0.383

Low

58 (52.7)

34 (53.1)

24 (52.2)

 

21 (50.0)

37 (54.4)

 

22 (47.8)

36 (56.3)

 

PLR

High

51 (46.4)

29 (45.3)

22 (47.8)

0.794

22 (52.4)

29 (42.6)

0.320

20 (43.5)

31 (48.4)

0.607

Low

59 (53.6)

35 (54.7)

24 (52.2)

 

20 (47.6)

39 (57.4)

 

26 (56.5)

33 (51.6)

 

SII

High

57 (51.8)

32 (50.0)

25 (54.4)

0.653

22 (52.4)

35 (51.5)

0.926

24 (52.2)

33 (51.6)

0.950

Low

53 (48.2)

32 (50.0)

21 (45.7)

 

20 (47.6)

33 (48.5)

 

22 (47.8)

31 (48.4)

 

PNI

High

59 (53.6)

36 (56.3)

23 (50.0)

0.517

20 (47.6)

39 (57.4)

0.320

25 (54.4)

34 (53.1)

0.899

Low

51 (46.4)

28 (43.7)

23 (50.0)

 

22 (52.4)

29 (42.6)

 

21 (45.6)

30 (46.9)

 

ALI

High

57 (51.8)

34 (53.1)

23 (50.0)

0.746

21 (50.0)

36 (52.9)

0.764

22 (47.8)

35 (54.7)

0.478

Low

53 (48.2)

30 (46.9)

23 (50.0)

 

21 (50.0)

32 (47.1)

 

24 (52.2)

29 (45.3)

 

GPS

High

44 (40.0)

23 (35.9)

21 (45.7)

0.305

14 (33.3)

30 (44.1)

0.262

16 (34.8)

28 (43.8)

0.344

Low

66 (60.0)

41 (64.1)

25 (54.4)

 

28 (66.7)

38 (55.9)

 

30 (65.2)

36 (56.3)

 

Leukocyte

High

59 (53.6)

37 (57.8)

22 (47.8)

0.300

23 (54.8)

36 (52.9)

0.852

30 (65.2)

29 (45.3)

0.039

Low

51 (46.4)

27 (42.2)

24 (52.2)

 

19 (45.2)

32 (47.1)

 

16 (34.8)

35 (56.7)

 

Neutrophil

High

59 (53.6)

36 (56.3)

23 (50.0)

0.517

23 (54.8)

36 (52.9)

0.852

29 (63.0)

30 (47.0)

0.094

Low

51 (46.4)

28 (43.8)

23 (50.0)

 

19 (45.2)

32 (47.1)

 

17 (37.0)

34 (53.1)

 

Lymphocyte

High

57 (51.8)

36 (56.3)

21 (45.6)

0.273

21 (50.0)

36 (52.9)

0.764

27 (58.7)

30 (46.9)

0.221

Low

53 (48.2)

28 (43.8)

25 (54.4)

 

21 (50.0)

32 (47.1)

 

19 (41.3)

34 (53.1)

 

Albumin

High

58 (52.7)

33 (51.6)

25 (54.4)

0.714

19 (45.2)

39 (57.4)

0.216

22 (47.8)

36 (56.3)

0.383

Low

52 (47.3)

31 (48.4)

21 (45.6)

 

23 (54.7)

29 (42.6)

 

24 (52.2)

28 (43.8)

 

CRP

High

54 (49.1)

32 (50.0)

22 (47.8)

0.822

25 (59.5)

29 (42.6)

0.085

24 (52.2)

30 (46.9)

0.583

Low

56 (50.9)

32 (50.0)

24 (52.2)

 

17 (40.5)

39 (57.4)

 

22 (47.8)

34 (53.1)

 

Ki-67

High

54 (49.1)

29 (46.8)

25 (54.4)

0.436

23 (54.8)

31 (47.0)

0.430

19 (43.2)

35 (54.7)

0.240

Low

56 (50.8)

33 (52.2)

21 (45.6)

 

19 (45.2)

35 (53.0)

 

25 (56.8)

29 (45.3)

 
  1. Cut-off values: NLR, 4.13; PLR, 240.6; SII, 134.1; PNI, 42.6; ALI, 18.1; Leukocyte, 7250; Neutrophil, 5302; Lymphocyte, 1223; Albumin, 3.6; CRP, 0.84; Ki-67 28.9. GPS was categorized as low (0) or high (1–2).
  2. AD, adenocarcinoma; ALI, advanced lung cancer inflammation index; CRP, C-reactive protein; ECOG, eastern cooperative oncology group; GPS, Glasgow prognostic score; Int., intensity; irAEs, immune-related adverse events; meta, metastasis; NLR, neutrophil to lymphocyte ratio; PD-L1, programmed death ligand-1; PLR, platelet to lymphocyte ratio; PNI, prognostic nutrition index; PR, partial response; Prop., proportion; PS, performance status; SII, systemic immune inflammation index; TROP2, Trophoblast surface antigen 2; yrs, years.
Back to article page